ICU
NASDAQSeaStar Medical Holding Corporation
News25/Ratings0
News · 26 weeks40-87%
2025-10-262026-04-19
Mix1990d
- Other8(42%)
- Insider7(37%)
- Earnings2(11%)
- SEC Filings2(11%)
Latest news
25 items- PRSeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026Results from pediatric patients in the SAVE Registry shows no device-related adverse events or immunosuppression and continued strong survival data In vitro analysis of the SeaStar Medical SCD indicates modulation of the immune response, shifting monocytes towards an anti-inflammatory, reparative phenotype SeaStar Medical hosts an industry symposium and panel discussion focused on innovation in the treatment of pediatric AKI, supporting its emerging leadership in this community DENVER, March 30, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ fai
- SECSEC Form 10-K filed by SeaStar Medical Holding Corporation10-K - SeaStar Medical Holding Corp (0001831868) (Filer)
- SECSeaStar Medical Holding Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SeaStar Medical Holding Corp (0001831868) (Filer)
- PRSeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesAdded top-rated children's hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeded 50% enrollment milestone in pivotal trial of SCD therapy in adult patients with AKI Advanced pipeline indications with initiation of cardio-renal clinical trial Webcast today at 4:30 pm Eastern Time DENVER, March 25, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and yea
- PRSeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2025 financial results after market close on Wednesday, March 25, 2026, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, March 25, 2026, at 4:30 p.m. ET / 2:30 p.m. MT Webcast:The live webcast and replay can be found here. Register for the call:Preregistration is required to attend the live call and can be accessed h
- PRLife Sciences Virtual Investor Forum Presentations Now Available for Online ViewingNEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry. REGISTER AND VIEW PRESENTATIONS HERE The presentations will be available 24/7 for 90 days. Investors,
- PRLife Sciences Virtual Investor Forum Agenda Announced for March 11th & 12thNEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science
- PRSeaStar Medical to Present at the Life Sciences Investor Forum on March 11thDENVER, March 09, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, CEO of SeaStar Medical, will participate in a fireside CEO chat with David Bautz, Senior Biotech Analyst at Zacks Small-Cap Research, at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 11, 2026. DATE: March 11th TIME: 12:00 pm E.T. REGISTER HERE Available for 1x1 meetings: March 11. Schedule 1x1 Meetings here. The event will be conducted as a live, interactive online forum, offe
- PRSeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKIDENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA that is designed to confirm the safety of the QUELIMMUNE™ therapy as a treatment for children with acute kidney injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT). The registry has successfully enrolled 50 patients, and the company will be reporting the 28-day safety results from the SAVE Registry to the FDA upon completion of its analysis of the data. "The early results from the SAVE Regis
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SeaStar Medical Holding CorporationSCHEDULE 13G/A - SeaStar Medical Holding Corp (0001831868) (Subject)
- INSIDERDirector Van Heel Kenneth was granted 3,000 shares, increasing direct ownership by 61% to 7,940 units (SEC Form 4)4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
- INSIDERDirector Neuman John was granted 3,000 shares, increasing direct ownership by 33% to 12,200 units (SEC Form 4)4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
- INSIDERDirector Baird Jennifer A was granted 3,000 shares, increasing direct ownership by 83% to 6,620 units (SEC Form 4)4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
- INSIDERDirector Vincent Bernadette N was granted 3,000 shares, increasing direct ownership by 250% to 4,200 units (SEC Form 4)4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
- INSIDERPrincipal Accounting Officer Towne Bradford K was granted 7,500 shares, increasing direct ownership by 484% to 9,050 units (SEC Form 4)4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
- INSIDERChief Medical Officer Chung Kevin was granted 15,000 shares, increasing direct ownership by 258% to 20,819 units (SEC Form 4)4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
- INSIDERChief Executive Officer Schlorff Eric was granted 30,000 shares, increasing direct ownership by 305% to 39,852 units (SEC Form 4)4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
- PRSeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)Strong survival data extending to 90 days Real-world experience shows results consistent with clinical trial data Favorable safety profile – no device-related adverse events DENVER, Feb. 09, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company, announced today the publication of early post-approval clinical experience from the use of the QUELIMMUNE (Selective Cytopheretic Device for Pediatrics, or SCD-PED) therapy in the prestigious, peer-reviewed journal Pediatric Nephrology. The publication, co-authored by leading experts including Stuart Goldstein, Kelli Krallman, Meredith Harris, Rajit Basu, David Askenazi, Shina Menon, Ma
- PRSeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity ConferenceDENVER, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on Thursday, February 5th at 11:30 am Eastern Time. Interested investors and guests of SeaStar Medical can register and view the live investor presentations here: Virtual Equity Conference Registration. A replay of the SeaStar Medical presentation will be available on Monday, February 9th aft
- SECSeaStar Medical Holding Corporation filed SEC Form 8-K: Other Events8-K - SeaStar Medical Holding Corp (0001831868) (Filer)
- PRSeaStar Medical Announces 2026 MilestonesDrive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer base Advance SeaStar Medical's first-in-class SCD therapy for the adult AKI indication – a potential $4.5 billion market – through completion of enrollment of the NEUTRALIZE-AKI pivotal trial and initiation of the PMA process Progress the clinical development of the SCD therapy in patients with severe heart failure Leverage rapid pathways to commercialization of the SCD therapy through additional FDA Humanitarian Use and Breakthrough Device Designations DENVER, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company fo
- PRSeaStar Medical to Present at Upcoming Biotech Showcase 2026 Investor ConferenceDENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at the Biotech Showcase 2026 Investor Conference at the Hilton Union Square, San Francisco, CA, on January 13, 2026, at 3:00 p.m. Pacific Standard Time. The live presentation will be available on the Company's website and can be accessed here. A replay of the presentation will be available at approximately 6:00 p.m. Pacific Standard Time on January 13, 2026, a
- SECAmendment: SeaStar Medical Holding Corporation filed SEC Form 8-K: Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits8-K/A - SeaStar Medical Holding Corp (0001831868) (Filer)
- PRSeaStar Medical Announces 1-for-10 Reverse SplitDENVER, Dec. 23, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today the Company's 1-for-10 reverse stock split (Reverse Split), which will become effective as of 12:01 a.m. Eastern Time on January 5, 2026. The Company's common stock will begin trading on a post-split adjusted basis on The Nasdaq Capital Market (Nasdaq) effective with the open of the market on January 5, 2026. SeaStar Medical's stock will continue to trade under the ticker symbol "ICU." Authorization for the Reverse Split was approved b
- INSIDERDirector Baird Jennifer A bought $987 worth of shares (4,200 units at $0.24), increasing direct ownership by 13% to 36,200 units (SEC Form 4)4 - SeaStar Medical Holding Corp (0001831868) (Issuer)